Suxilon Equidos 1.5 g Granules for Top Dressing

Main information

  • Trade name:
  • Suxilon Equidos 1.5 g Granules for Top Dressing
  • Pharmaceutical form:
  • Granules
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Suxilon Equidos 1.5 g Granules for Top Dressing
    Austria
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Suxibuzone
  • Therapeutic area:
  • Horses

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0372/001
  • Authorization date:
  • 18-05-2011
  • EU code:
  • UK/V/0372/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:June2011

AN:00389/2010

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Danilonequidos1.5gGranules

Suxilon1.5gGranulesfortopdressing(onlyforUK)

Suxibuzone

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Each10gsachetcontains

Activesubstance:

Suxibuzone(microencapsulated)1.5g

Excipient(s):

Quinolineyellow(E104)2.5mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Granules

Yellowandodourlessgranules.

4. CLINICALPARTICULARS

4.1Targetspecies

Horsesandponies.

4.2Indicationsforuse,specifyingthetargetspecies

Treatmentofpainandinflammationassociatedwithmusculo-skeletalconditionsinthehorse

egosteoarthriticconditions,bursitis,laminitisandsofttissueinflammation.

4.3Contraindications

Donotadministertoanimalswithrenal,hepaticorcardiacdisorders;wherethereisthe

possibilityofgastro-intestinalulcerationorbleeding,orwherethereisevidenceofablood

dyscrasiaorhypersensitivitytotheproduct.

4.4Specialwarningsforeachtargetspecies

Donotadministerpriortotakingpartinacompetition.

Duringtreatmentofveryyounganimals(lessthan12weeks)wheredevelopmentoftheir

hepaticorrenalfunctionmaybeincomplete,orinagedanimalswhichmayhavethese

functionsimpaired,aswellasinponies,additionalriskmaybeinvolved.Inthesecases,

dosesshouldbeaccuratelycalculatedandpatientsmonitoredclosely.

Issued:June2011

AN:00389/2010

Duringtreatment,donotrestricttheconsumptionofwater.Avoiduseinanydehydrated,

hypovolaemicorhypotensiveanimalsastheremaybeanincreasedriskofrenalfailure.

NSAIDscancauseinhibitionofphagocytosisandhence,inthetreatmentofinflammatory

conditionsassociatedwithbacterialinfectionsappropriateantimicrobialtherapyshouldbe

instigated.

4.5Specialprecautionsforuse

4.5.iSpecialprecautionsforuseinanimals

Duringtreatmentdonotrestricttheconsumptionofwater.

Donotexceedthestateddoseordurationoftreatment.Dosageshouldbekepttoa

minimumforalleviationofsymptoms.

4.5.iiSpecialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Wearsuitablegloves.Washhandsafteruse.

Useinawell-ventilatedarea.Avoidinhalinganydustwhenopeningsachetandmixingwith

feed.Incaseofaccidentalcontactwitheyes,washimmediatelywithplentyofcleanwater.

Incaseofaccidentalingestion,seekmedicaladviceimmediatelyandshowthislabeltothe

physician.

4.6Adversereactions(frequencyandseriousness)

Aftercontinueduse,orathighdosesgastro-intestinalchangesmayoccur.Occasionally

blooddyscrasiasandrenalalterationsmaybefound,especiallyinanimalswithrestricted

accesstowater.

4.7Useduringpregnancy,lactationorlay

Thesafetyoftheveterinarymedicinalproducthasnotbeenestablishedduringpregnancy

andlactation,thereforeuseduringtheseperiodsisnotrecommended.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Suxibuzoneanditsmetabolitesmaybehighlyboundtoplasmaproteinsandcompetewith

otherhighlybounddrugsegsulphonamides,warfarin;oritmayitselfbedisplacedto

produceanincreaseofnon-boundpharmacologicallyactiveconcentrationswhichcouldlead

totoxiceffects.Drugcompatibilitymustbecloselymonitoredwhenadjunctivetherapyis

required.

DonotadministertogetherwithotherNSAIDsconcurrentlyorwithin24hoursofeachother.

Concurrentadministrationofpotentiallynephrotoxicdrugsshouldbeavoided.

Issued:June2011

AN:00389/2010

4.9Amountstobeadministeredandadministrationroute

Fororaladministration.

Whenaddedtoaportionoffeedtheproductwillbeacceptedbymosthorses.

Thefollowingshouldbeusedasaguide,accordingtoindividualresponse:

Horses

Fora480kgbodyweighthorse,thecontentsof2sachetsshouldbeadministeredtwicedaily

(equivalentto12.5mgofsuxibuzone/kg/day)for2days,followedby1sachettwicedaily

(6.25mgofsuxibuzone/kg/day)for3days.

Thereafter,1sachetdaily(3.1mgofsuxibuzone/kg/day)oronalternatedays,orthe

minimumdosenecessaryforasatisfactoryclinicalresponse.

Ponies(breedsoflessthan149cmhighatthewitherswhenfullgrown)

Poniesshouldreceiveonlyhalfthedoseraterecommendedforhorses.

Fora240kgbodyweightpony,thecontentsof1sachetshouldbeadministereddaily

(equivalentto6.25mgofsuxibuzone/kg/day)for2days,followedby1/2sachetdaily(3.1

mgofsuxibuzone/kg/day)for3daysor1sachetonalternatedays.

Thereafter,reducethedosetotheminimumdosenecessaryforasatisfactoryclinical

response.

Foradministrationoflessthanonesachet,usethemeasuringscoopprovided.Onefulllevel

scoopcontains5ggranules(equivalentto1/2sachet)anduptothegreenlinelevel

contains2,5ggranules(equivalentto1/4sachet).

Hay,aspartofthediet,maydelaytheabsorptionofsuxibuzoneandsotheonsetofclinical

effect.Itisadvisablenottofeedhayimmediatelypriorto,orwiththismedicinalproduct.

Seealso4.4.

Ifnoclinicalresponseisevidentafter4-5days,discontinuetreatmentandreconsiderthe

diagnosis.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Incaseofcontinuousoverdose,thefollowingsignsmaybeobserved:

Thirst,depression,anorexiaandweightloss.

Gastrointestinaldisorders(irritation,ulcers,diarrhoeaandbloodinthefaeces).

Alteredbloodprofilesandhaemorrhages.

Hypoproteinemiawithventraloedemacausinghemoconcentration,hypovolemicshock

andcirculatorycollapse.

Renalfailureandfluidretention.

Ifsignsofintoleranceappear,discontinuetreatmentandestablishsymptomatictherapy.

Aslowintravenousperfusionofasolutionofsodiumbicarbonate,whichleadstourine

alkalinisation,increasestheclearanceoftheproduct.

Issued:June2011

AN:00389/2010

4.11Withdrawalperiod(s)

Nottobeusedinanimalsintendedforhumanconsumption.

Treatedhorsesmayneverbeslaughteredforhumanconsumption.

Thehorsemusthavebeendeclaredasnotintendedforhumanconsumptionundernational

horsepassportlegislation.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antiinflamatoryandantirheumaticproducts,non-steroids,

butylpyrazolidines,suxibuzone.

ATCvetcode:QM01AA90

5.1Pharmacodynamicproperties

SuxibuzoneisaNon-SteroidalAnti-inflammatoryDrug(NSAID)syntheticallyderivedfrom

pyrazolonewithanti-inflammatory,antipyreticandanalgesicpropertieswithlowulcerogenic

potential.

Whenmixedwithconcentratefeed,theproductwasshowntobepalatabletohorses.

Itsmechanismofactionisbasedontheinhibitionofthecyclooxygenase(enzymewhich

catalyzesthesynthesisofprostaglandins,prostacyclinesandthromboxanesfrom

arachidonicacid).Thetherapeuticeffectsaremainlyduetotheinhibitionofthebiosynthesis

ofprostaglandines,whichactasperipheralmediatorsofpainandtriggerthesynthesisof

endogenpyrogensandmediatorsintheinflammatoryprocess.Italsoinhibitsplatelet

aggregation.

Thetherapeuticeffectofsuxibuzonereliesentirelyontheactivityofitsactivemetabolites.

Strong anti-inflammatory activity has been shown for phenylbutazone and

oxyphenbutazone.Thethirdmetabolite 

-hydroxyphenilbutazoneisconsideredtobe

pharmacologicallyinactive.

5.2Pharmacokineticparticulars

Afteroraladministrationsuxibuzoneisreadilyabsorbedandmostofitismetabolisedbythe

hepaticmicrosomalsystemproducingphenylbutazone,oxyphenbutazoneand 

hydroxyphenylbutazone.Nounalteredparentcompoundcanbedetectedinplasmaafter

oraladministrationofsuxibuzonetohorsesorponies.Theseactivemetaboliteshaveahigh

degreeofaffinityforplasmaproteinsandareeliminatedmainlythroughurine,as

glucoronideconjugates,butalso,inasmallpercentage,throughfaeces.Lessthan1%is

eliminatedthroughsalivaandmilk.

Aftertheadministrationofasingle6.25mg/kgoraldoseoftheparentcompound

phenylbutazonereachesitsmaximumplasmaconcentration(10µg/ml)at4-5-hoursafter

administration.Oxyphenbutazonereachesitsmaximum(2.1µg/ml)at15hoursafter

administration.Bothmetaboliteshaveaneliminationhalflifeof5-6h.

AshappenswithotherNSAID´sthedurationoftheclinicalresponseismuchlongerthanthe

plasmahalf-life.Significantconcentrationsofbothactivemetabolitesarefoundinsynovial

fluidforatleast24hoursafteradministration.

Issued:June2011

AN:00389/2010

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Quinolineyellow(E104)

Mannitol

Sucrose

PovidoneK-30

Sodiumsaccharin

EthylCellulose20

6.2Incompatibilities

Noneknown.

6.3Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:4years

Shelflifeafterfirstopeningofthesachet:7days.

6.4.Specialprecautionsforstorage

Afteropeningasachetre-sealaswellaspossiblebetweendoses.

Thismedicinalproductdoesnotrequireanyspecialstorageconditions.

6.5Natureandcompositionofimmediatepackaging

Cartoncontaining18x10gor60x10gcoatedpaper,aluminiumfoilandpolyethylene

sachetswith5gspoon(whenlevel)and2.5gincrementdosingdevice.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductsshouldbedisposedofinaccordancewithlocalrequirements.

Issued:June2011

AN:00389/2010

7. MARKETINGAUTHORISATIONHOLDER

LaboratoriosDr.ESTEVE,S.A.

Avda.MaredeDéudeMontserrat,221

08041 –Barcelona

Spain

8. MARKETINGAUTHORISATIONNUMBER

Vm08498/4006

9. DATEOFFIRSTAUTHORISATION

14June2011

10 DATEOFREVISIONOFTHETEXT

June2011

29-6-2018

Wish Bone Salad Dressing Issues Allergy Alert On Undeclared Milk and Egg in 15 oz. Wish-Bone House Italian Salad Dressing

Wish Bone Salad Dressing Issues Allergy Alert On Undeclared Milk and Egg in 15 oz. Wish-Bone House Italian Salad Dressing

Pinnacle Foods Inc. is voluntarily recalling a limited quantity of Wish Bone House Italian Salad Dressing 15 oz. with the health and safety of our consumers as our top priority. The recall was initiated after learning from a retail customer that a limited number of bottles were mislabeled. The product contains milk and egg, known allergens not declared on the bottle. People who have an allergy or severe sensitivity to milk or egg may run the risk of a serious or life-threatening allergic reaction if t...

FDA - U.S. Food and Drug Administration

26-5-2018

Stop & Shop Voluntarily Recalls Stop & Shop Frozen Broccoli Cuts

Stop & Shop Voluntarily Recalls Stop & Shop Frozen Broccoli Cuts

Stop & Shop is voluntarily recalling Private Brand Frozen Broccoli Cuts (16 oz.) with sell by date of Mar 15, 2020 and UPC code 68826700926 out of an abundance of caution due to our supplier notifying us the product may have Listeria monocytogenes.

FDA - U.S. Food and Drug Administration

There are no news related to this product.